Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Ernesto Rossi, Brigida Anna Maiorano, Monica Maria Pagliara, Maria Grazia Sammarco, Tommaso Dosa, Maurizio Martini, Guido Rindi, Emilio Bria, Maria Antonietta Blasi, Giampaolo Tortora, Giovanni Schinzari

Research output: Contribution to journalArticle

Abstract

Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.

Original languageEnglish
Pages (from-to)232
JournalFrontiers in Oncology
Volume9
DOIs
Publication statusPublished - 2019

    Fingerprint

Cite this

Rossi, E., Maiorano, B. A., Pagliara, M. M., Sammarco, M. G., Dosa, T., Martini, M., Rindi, G., Bria, E., Blasi, M. A., Tortora, G., & Schinzari, G. (2019). Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma. Frontiers in Oncology, 9, 232. https://doi.org/10.3389/fonc.2019.00232